Therapeutic role of mesenchymal stem cells (MSCs) in diabetic kidney disease (DKD)

8Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Findings of preclinical studies and recent phase I/II clinical trials have shown that mesenchymal stem cells (MSCs) play a significant role in the development of diabetic kidney disease (DKD). Thus, MSCs have attracted increasing attention as a novel regenerative therapy for kidney diseases. This review summarizes recent literature on the roles and potential mechanisms, including hyperglycemia regulation, anti-inflammation, anti-fibrosis, pro-angiogenesis, and renal function protection, of MSC-based treatment methods for DKD. This review provides novel insights into understanding the pathogenesis of DKD and guiding the development of biological therapies.

Cite

CITATION STYLE

APA

Xu, N., Liu, J., & Li, X. (2022). Therapeutic role of mesenchymal stem cells (MSCs) in diabetic kidney disease (DKD). Endocrine Journal. Japan Endocrine Society. https://doi.org/10.1507/endocrj.EJ22-0123

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free